Cryo-Cell International, Inc. (CCEL)
- Previous Close
5.0100 - Open
4.9500 - Bid 4.9000 x 1400
- Ask 4.9500 x 900
- Day's Range
4.9009 - 4.9499 - 52 Week Range
4.7500 - 9.4900 - Volume
6,900 - Avg. Volume
13,072 - Market Cap (intraday)
39.61M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
490.09 - EPS (TTM)
0.0100 - Earnings Date Jul 14, 2025 - Jul 18, 2025
- Forward Dividend & Yield 0.60 (11.98%)
- Ex-Dividend Date May 21, 2025
- 1y Target Est
8.50
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
www.cryo-cell.com82
Full Time Employees
November 30
Fiscal Year Ends
Sector
Industry
Recent News: CCEL
View MorePerformance Overview: CCEL
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CCEL
View MoreValuation Measures
Market Cap
40.49M
Enterprise Value
50.87M
Trailing P/E
397.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.26
Price/Book (mrq)
--
Enterprise Value/Revenue
1.58
Enterprise Value/EBITDA
8.70
Financial Highlights
Profitability and Income Statement
Profit Margin
0.40%
Return on Assets (ttm)
3.99%
Return on Equity (ttm)
--
Revenue (ttm)
32.1M
Net Income Avi to Common (ttm)
128.71k
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.07M